AU5348301A - Naphthalimide compositions and uses thereof - Google Patents

Naphthalimide compositions and uses thereof

Info

Publication number
AU5348301A
AU5348301A AU5348301A AU5348301A AU5348301A AU 5348301 A AU5348301 A AU 5348301A AU 5348301 A AU5348301 A AU 5348301A AU 5348301 A AU5348301 A AU 5348301A AU 5348301 A AU5348301 A AU 5348301A
Authority
AU
Australia
Prior art keywords
naphthalimide
agents
compositions
host
proliferative disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU5348301A
Other languages
English (en)
Inventor
Dennis M Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ChemGenex Pharmaceuticals Inc
Original Assignee
ChemGenex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ChemGenex Therapeutics Inc filed Critical ChemGenex Therapeutics Inc
Publication of AU5348301A publication Critical patent/AU5348301A/xx
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU5348301A 2000-04-12 2001-04-12 Naphthalimide compositions and uses thereof Withdrawn AU5348301A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19710300P 2000-04-12 2000-04-12
PCT/US2001/012169 WO2001078705A2 (en) 2000-04-12 2001-04-12 Compositions containing a naphthalmide and an antiproliferative agent

Publications (1)

Publication Number Publication Date
AU5348301A true AU5348301A (en) 2001-10-30

Family

ID=22728064

Family Applications (1)

Application Number Title Priority Date Filing Date
AU5348301A Withdrawn AU5348301A (en) 2000-04-12 2001-04-12 Naphthalimide compositions and uses thereof

Country Status (10)

Country Link
US (2) US6630173B2 (https=)
EP (1) EP1274458B1 (https=)
JP (1) JP2003530431A (https=)
AT (1) ATE305312T1 (https=)
AU (1) AU5348301A (https=)
CA (1) CA2404278C (https=)
DE (1) DE60113666T2 (https=)
ES (1) ES2248312T3 (https=)
HK (1) HK1052874B (https=)
WO (1) WO2001078705A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1263440E (pt) * 2000-03-15 2006-11-30 Chemgenex Pharmaceuticals Inc Composições de combinação do alcalóide cefalotaxina e sua utilização
US7135481B2 (en) * 2000-04-12 2006-11-14 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US20060211648A1 (en) * 2000-04-12 2006-09-21 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
ATE305312T1 (de) * 2000-04-12 2005-10-15 Chemgenex Pharmaceuticals Inc Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten
US20050170015A1 (en) * 2000-10-31 2005-08-04 Brown Dennis M. Antiproliferative colchicine compositions and uses thereof
US20050239816A1 (en) * 2002-04-22 2005-10-27 Xanthus Life Sciences, Inc. Amonafide salts
US6693198B2 (en) * 2002-04-22 2004-02-17 Xanthus Life Sciences, Inc. Amonafide salts
JP2005529123A (ja) * 2002-04-24 2005-09-29 リサーチ　ディベロップメント　ファンデーション 核転写調節因子ＮＦ−κＢ抑制剤と抗腫瘍薬の相乗効果
US20040082788A1 (en) * 2002-07-08 2004-04-29 Chemgenex Therapeutics, Inc. Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof
US20040082565A1 (en) * 2002-07-17 2004-04-29 Chemgenex Therapeutics, Inc. Formulations and methods of administration of cephalotaxines including homoharringtonine
WO2004009030A2 (en) * 2002-07-22 2004-01-29 Chemgenex Pharmaceuticals Limited Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
AU2005209845A1 (en) * 2004-01-30 2005-08-18 Chemgenex Pharmaceuticals, Inc. Naphthalimide dosing by N-acetyl transferase genotyping
JP2008501719A (ja) * 2004-06-04 2008-01-24 ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド ナフタルイミドおよびｐａｒｐ−１インヒビターを使用する細胞増殖性疾患の処置方法
JP2008529667A (ja) * 2005-02-10 2008-08-07 ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド 医療デバイス
AU2008240044B2 (en) * 2007-04-13 2013-09-12 Teva Pharamceuticals International Gmbh Oral cephalotaxine dosage forms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183821A (en) * 1983-09-19 1993-02-02 Laboratories Knoll, S.A. Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors
US5420137A (en) 1989-07-11 1995-05-30 Knoll Ag Amonafide salts
FR2673944B1 (fr) * 1991-03-13 1995-03-10 Sanofi Elf Derives de l'1,8-naphtalimide, leur procede de preparation et les compositions pharmaceutiques les contenant.
CA2294247C (en) * 1997-07-01 2004-10-26 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
PT1263440E (pt) 2000-03-15 2006-11-30 Chemgenex Pharmaceuticals Inc Composições de combinação do alcalóide cefalotaxina e sua utilização
AU2001247649A1 (en) * 2000-03-21 2001-10-30 Atherogenics, Inc N-substituted dithiocarbamates for the treatment of biological disorders
ATE305312T1 (de) * 2000-04-12 2005-10-15 Chemgenex Pharmaceuticals Inc Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten

Also Published As

Publication number Publication date
EP1274458A2 (en) 2003-01-15
JP2003530431A (ja) 2003-10-14
WO2001078705A3 (en) 2002-06-20
US6630173B2 (en) 2003-10-07
ES2248312T3 (es) 2006-03-16
US20040047918A1 (en) 2004-03-11
CA2404278C (en) 2010-03-23
EP1274458B1 (en) 2005-09-28
ATE305312T1 (de) 2005-10-15
CA2404278A1 (en) 2001-10-25
HK1052874A1 (en) 2003-10-03
WO2001078705A2 (en) 2001-10-25
DE60113666D1 (de) 2005-11-03
DE60113666T2 (de) 2006-06-14
US20020025916A1 (en) 2002-02-28
HK1052874B (en) 2006-05-04

Similar Documents

Publication Publication Date Title
AU5348301A (en) Naphthalimide compositions and uses thereof
AU4580301A (en) Cephalotaxine alkaloid compositions and uses thereof
WO2001004357A3 (en) Generic sbe-fret protocol
AP2001002319A0 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
ZA200202479B (en) Heterocyclic sodium/proton exchange inhibitors and method.
CA2400554A1 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
ATE425165T1 (de) Verfahren zur zubereitung von inhibitoren des nukleosid-metabolismus
IL150641A0 (en) Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
UA103873C2 (ru) Гетероарильные производные мочевины как ингибиторы р38 и их применение
SI1075477T1 (en) Novel Benzonaphthyridine-N-oxides
AU2003241311A8 (en) Simple catalytic dna biosensors for ions based on color changes
BR0109577A (pt) Composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, método para tratar cânceres em um animal de sangue quente
PL334561A1 (en) Novel phtalysinones
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
MY136037A (en) Biphenyl pyrimidone lp-pla2 inhibitors
IL157694A0 (en) Method of determining dihydropyrimidine dehydrogenase gene expression
WO2001091741A3 (en) Compositions containing hexitol and an antiproliferative agent
ATE411815T1 (de) Methylierte immunstimulierende oligodeoxynukleotide und verfahren zu deren verwendung
EP1583839A3 (en) METHODS OF CAPTURING, DETECTING AND QUANTIFYING RNA:DNA HYBRIDS AND A MODIFIED RNase H USEFUL THEREIN
EP1201765A3 (en) Cellular kinases involved in cytomegalovirus infection and their inhibition
WO2000061594A3 (de) Nucleosid-derivate mit photolabilen schutzgruppen
WO2002051848A3 (de) Sulfamidothienopyrimidine zur verwendung als phosphodiesterase v-hemmer
HUP0300183A3 (en) Substituted purine derivatives as inhibitors of cell adhesion
AU2003215161A1 (en) RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2007095639A3 (en) Napht alimide compositions and uses thereof

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired